|
gptkbp:instanceOf
|
gptkb:drug
peptide
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvalYear
|
2010
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
A10BJ02
|
|
gptkbp:brand
|
gptkb:Victoza
gptkb:Saxenda
|
|
gptkbp:CASNumber
|
gptkb:204656-20-2
|
|
gptkbp:contraindication
|
gptkb:medullary_thyroid_carcinoma
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
|
|
gptkbp:developer
|
gptkb:Novo_Nordisk
|
|
gptkbp:discoveredBy
|
gptkb:Novo_Nordisk
|
|
gptkbp:eliminationHalfLife
|
13 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C172H265N43O51
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
liraglutide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
GLP-1 receptor agonist
|
|
gptkbp:metabolism
|
proteolytic cleavage
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
>98%
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
pancreatitis
|
|
gptkbp:UNII
|
839I73S42A
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes
obesity
|
|
gptkbp:bfsParent
|
gptkb:GLP-1_receptor_agonists
|
|
gptkbp:bfsLayer
|
6
|